NASH fEVs increase the production of extracellular matrix proteins and chemokines/cytokines production in hepatic stellate (LX‐2 cells), alter hepatocyte integrity and decrease ZO‐1 and occludin protein levels. The gene discussed is TJP1; the disease is metabolic dysfunction-associated steatohepatitis.